Final Logo-01.png
PARP Inhibitor Market to Surpass USD 67.0 Billion by 2034, with 18.30% CAGR and Redefining Cancer Treatment Landscape - By PMI
27 févr. 2024 14h30 HE | PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the PARP Inhibitor Market size was valued at about USD 12.5 Billion in 2024 and expected to grow at CAGR of 18.30%...
Charting New Paths:
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23 févr. 2024 13h50 HE | Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Final Logo-01.png
Biopharmaceutical and Biomedicine Market Size & Share to Exceed USD 1803.2 Billion by 2034, at CAGR of 12.20%. “Harnessing the Power of Genomics for Precision Medicine"– By PMI
12 févr. 2024 19h30 HE | PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Biopharmaceutical and Biomedicine Market size was valued at about USD 570.0 Billion in 2024 and expected to...
Final Logo-01.png
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
08 févr. 2024 17h30 HE | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Complex Disease Treatment Market Size & Share to Exceed USD 748.5 billion by 2034, at CAGR of 13.1%. Overview, Analysis, Dynamics, Report, Trend/Opportunities, Segmentation, Players, Growth Rate/Value - By PMI
01 févr. 2024 13h00 HE | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Complex Disease Treatment Market size was valued at about USD 244.4 billion in 2024 and expected to grow at...
Related Sciences - Press Logo.png
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
19 déc. 2023 10h00 HE | Related Sciences
Former CEOs and executives from Genentech, Novartis, Seagen, Pfizer, and Celgene join drug AI/ML drug discovery firm Related Sciences as senior advisors.
When it Comes to Tre
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
30 nov. 2023 10h59 HE | Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
Dyadic Logo Current.jpg
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
20 nov. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
US Gastroenterologis
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
13 nov. 2023 09h22 HE | Spherix Global Insights
Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
Pfizer und BioNTech
Pfizer und BioNTech geben erste positive Daten für mRNA-basiertes Kombinationsimpfstoffprogramm gegen Influenza und COVID-19 bekannt
26 oct. 2023 06h45 HE | BioNTech SE
Die in der Phase-1/2-Studie untersuchten führenden Kombi-Impfstoffformulierungen zeigten robuste Immunantworten gegen Influenza A, Influenza B und SARS-CoV-2-Stämme  Das Sicherheitsprofil der...